A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression rates.

Based on these results, the FDA approved pembrolizumab for BCG-unresponsive high-risk NMIBC with carcinoma in situ who are ineligible for or have elected to forgo cystectomy.

If you’ve missed our conversations with other experts in the oncological field, be sure to check out our Spotlight On page ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under ...

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CG Oncology, Inc.